Chest:伴有房颤的脓毒症患者使用苯肾上腺素和去甲肾上腺素后对心率效应的比较

2022-05-26 MedSci原创 MedSci原创

在伴有房颤的脓毒症患者中,与去甲肾上腺素相比,使用苯肾上腺素与心率轻度降低相关。在开始升压时的心率似乎是一个重要的效应调节因子。

心房颤动(AF)是脓毒症常见的并发症。目前尚不清楚α-和β-激动剂去甲肾上腺素和α-激动剂苯肾上腺素是否与伴有房颤的脓毒症患者不同心率之间存在相关性。

近日,呼吸领域权威杂志chest上发表了一篇研究文章,研究人员旨在明确在伴有房颤的脓毒症患者中使用苯肾上腺素和去甲肾上腺素后对心率的影响有何不同?

研究人员利用重症监护医疗信息(MIMIC)-IV数据库,确定了在开始使用去甲肾上腺素或苯肾上腺素时治疗的伴有房颤的脓毒症患者。此外,研究人员采用多变量校正线性回归法评估了在使用苯肾上腺素或去甲肾上腺素开始升压后1小时和6小时的患者心率差异,并评估了心率对疗效的影响,同时,根据基线心率≥110bpm或<110bpm进行了分层。该研究的次要结局包括转换为窦性心律、心动过缓、升压药物使用时间、重症监护室(ICU)和住院时间,以及医院死亡率。研究人员采用间断时间序列的敏感性分析来估计接受苯肾上腺素和去甲肾上腺素治疗的患者平均心率之间的差异。

1847例伴有房颤的脓毒症患者中,946例(51%)患者接受了去甲肾上腺素治疗,901例(49%)患者接受了苯肾上腺素治疗。多变量调整后,苯肾上腺素与1小时(-4bpm[95%CI为-6,-1],p<0.001)和6小时(-4bpm[-6,-1],p=0.004)心率降低相关。与去甲肾上腺素相比,使用苯肾上腺素的患者在给药前心率较高与心率降低幅度较大相关。两组间次要结局无显著差异。探索性分析和敏感性分析结果两组也相似。

由此可见,在伴有房颤的脓毒症患者中,与去甲肾上腺素相比,使用苯肾上腺素与心率轻度降低相关。在开始升压时的心率似乎是一个重要的效应调节因子。但心率适度降低是否与临床结果相关,还需要进一步研究。

 

原始出处:

Anica C. Law.et al.Comparison of heart rate after phenylephrine versus norepinephrine initiation in patients with septic shock and atrial fibrillation.chest.2022.https://journal.chestnet.org/article/S0012-3692(22)00891-1/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929692, encodeId=f852192969258, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 01 14:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895257, encodeId=4f11189525eb0, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Feb 09 05:47:24 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051783, encodeId=83292051e8315, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 07 03:47:24 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284952, encodeId=935a128495225, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516389, encodeId=36ba151638947, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
    2022-11-01 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929692, encodeId=f852192969258, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 01 14:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895257, encodeId=4f11189525eb0, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Feb 09 05:47:24 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051783, encodeId=83292051e8315, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 07 03:47:24 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284952, encodeId=935a128495225, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516389, encodeId=36ba151638947, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929692, encodeId=f852192969258, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 01 14:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895257, encodeId=4f11189525eb0, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Feb 09 05:47:24 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051783, encodeId=83292051e8315, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 07 03:47:24 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284952, encodeId=935a128495225, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516389, encodeId=36ba151638947, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929692, encodeId=f852192969258, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 01 14:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895257, encodeId=4f11189525eb0, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Feb 09 05:47:24 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051783, encodeId=83292051e8315, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 07 03:47:24 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284952, encodeId=935a128495225, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516389, encodeId=36ba151638947, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929692, encodeId=f852192969258, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 01 14:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895257, encodeId=4f11189525eb0, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Feb 09 05:47:24 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051783, encodeId=83292051e8315, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 07 03:47:24 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284952, encodeId=935a128495225, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516389, encodeId=36ba151638947, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu May 26 11:47:24 CST 2022, time=2022-05-26, status=1, ipAttribution=)]

相关资讯

JACC:新晋“坏”血脂LPa升高居然会增加心房颤动的风险

Lp(a)是房颤发展过程中的一个潜在的因果媒介,这表明Lp(a)的影响延伸至整个心肌组织。

高手必备:14种房颤治疗用药知识大盘点!

快速读懂房颤的药物治疗。

Stroke:伴有房颤的脑出血幸存者脑血管事件的风险

研究人员观察到脑出血一年后具有较高的脑血管缺血性事件和全因死亡风险。正在进行的临床试验的结果需要进一步证实在伴有房颤的脑出血幸存者中最佳的卒中预防治疗。

JAHA:肾功能和房颤之间的双向关联

肾功能,尤其是eGFRcys,与房颤之间存在双向相关性。目前还没有针对轻度慢性肾病患者的房颤的预防措施,反之亦然。该研究的结果为改善这两种疾病的预测/预防提供了初步依据。

JAHA:血浆总同型半胱氨酸水平与伴有房颤的缺血性卒中患者不良结局相关

血浆中较高的总同型半胱氨酸水平与AF相关卒中患者的不良结局相关。这种正相关可能因肾功能而异,但需要在进一步的研究中加以验证。

JAMA Cardiol:耄耋之年房颤患者服用小剂量依度沙班的疗效和安全性

80岁及以上的房颤患者,服用小剂量依度沙班可降低卒中和全身栓塞事件的发生风险,且不显著增加出血事件风险